CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk Patient-tailored antithrombotic therapy following percutaneous coronary intervention Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention Individualized antiplatelet therapy after drug-eluting stent deployment: Implication of clinical trials of different durations of dual antiplatelet therapy Ticagrelor With or Without Aspirin After Complex PCI Osteoarthritis risk is reduced after treatment with ticagrelor compared to clopidogrel: a propensity score matching analysis Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial

ConsensusOctober 10, 2017, Volume 136, Issue 15

JOURNAL:Circulation. Article Link

Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association

AHA Scientific Statements Keywords: AHA Scientific Statements; delivery of health care; disease management; shock, cardiogenic

ABSTRACT

Cardiogenic shock is a high-acuity, potentially complex, and hemodynamically diverse state of end-organ hypoperfusion that is frequently associated with multisystem organ failure. Despite improving survival in recent years, patient morbidity and mortality remain high, and there are few evidence-based therapeutic interventions known to clearly improve patient outcomes. This scientific statement on cardiogenic shock summarizes the epidemiology, pathophysiology, causes, and outcomes of cardiogenic shock; reviews contemporary best medical, surgical, mechanical circulatory support, and palliative care practices; advocates for the development of regionalized systems of care; and outlines future research priorities.